Saturday 17 October 2026
Export MNPR’s income statement to Excel — free account
Monopar Therapeutics Inc.
MNPR Healthcare Biotechnology
In the quarter to June 2026, EPS fell 77.1% and free cash flow fell 201.4%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
69.27
2.53
−3.52%
Follow MNPR
Monopar Therapeutics Inc. (MNPR) P/E ratio
Monopar Therapeutics Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| RGNX REGENXBIO Inc. compare | n/m |
| MNPR Monopar Therapeutics Inc. | n/m |
| NGNE Neurogene Inc. compare | n/m |
| ALT Altimmune, Inc. compare | n/m |
| CBIO Crescent Biopharma, Inc. compare | n/m |
| ENTX Entera Bio Ltd. compare | n/m |
| ALLO Allogene Therapeutics, Inc. compare | n/m |
| ARVN Arvinas, Inc. compare | 53.6× |
| YDES YD Bio Limited compare | — |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)